Julie Taguchi

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study

Sandra M. Swain, David Miles, Sung‐Bae Kim et al. · The Lancet Oncology · 2020 · 898 citations

Medicine, Oncology, Pharmacology +14

Afatinib alone or afatinib plus vinorelbine versus investigator's choice of treatment for HER2-positive breast cancer with progressive brain metastases after trastuzumab, lapatinib, or both (LUX-Breast 3): a randomised, open-label, multicentre, phase 2 trial

Javier Cortés, Véronique Dièras, Jungsil Ro et al. · The Lancet Oncology · 2015 · 129 citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Phase Ib/II single-arm trial evaluating the combination of everolimus, lapatinib and capecitabine for the treatment of HER2-positive breast cancer with brain metastases (TRIO-US B-09)

Sara A. Hurvitz, Rashi Singh, Brad Adams et al. · Therapeutic Advances in Medical Oncology · 2018 · 31 citations · Full text

Medicine, Oncology, Pharmacology +17

A phase II study of neoadjuvant docetaxel/carboplatin with or without trastuzumab in locally advanced breast cancer: Response and cardiotoxicity

HR Chang, DJ Slamon, Raquel Prati et al. · Journal of Clinical Oncology · 2006 · 24 citations

Medicine, Oncology, Pharmacology +17

Craniospinal arachnoid cyst: case report.

Yuta Fukushima, M. Sato, Julie Taguchi et al. · PubMed · 1996 · 11 citations

Medicine, Neurosurgery, Radiology +13